CN110664795A - Water-soluble composition, preparation method and application thereof - Google Patents

Water-soluble composition, preparation method and application thereof Download PDF

Info

Publication number
CN110664795A
CN110664795A CN201910894304.XA CN201910894304A CN110664795A CN 110664795 A CN110664795 A CN 110664795A CN 201910894304 A CN201910894304 A CN 201910894304A CN 110664795 A CN110664795 A CN 110664795A
Authority
CN
China
Prior art keywords
formula
compound
unsubstituted
substituted
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910894304.XA
Other languages
Chinese (zh)
Other versions
CN110664795B (en
Inventor
张兵
张炽坚
伍宇飞
何廷刚
胡丽云
艾勇
张文环
屈恋
克里斯特勒热夫雷
弗兰克吉隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Heji Biotechnology Co Ltd
Original Assignee
Guangdong Heji Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Heji Biotechnology Co Ltd filed Critical Guangdong Heji Biotechnology Co Ltd
Priority to CN201910894304.XA priority Critical patent/CN110664795B/en
Publication of CN110664795A publication Critical patent/CN110664795A/en
Priority to PCT/CN2020/114939 priority patent/WO2021052269A1/en
Application granted granted Critical
Publication of CN110664795B publication Critical patent/CN110664795B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to the field of magnolia officinalis total phenol derivatives, and discloses a water-soluble composition which is composed of compounds with structures of a formula (1) and a formula (2). The magnolia total phenol derivative prepared by the invention has good water solubility, is colorless and transparent after being dissolved, has obvious inhibition effect on common gram-negative bacteria, gram-positive bacteria, fungi and the like, and can be used as a green natural preservative to be applied to the fields of food, medicines, cosmetics and the like.

Description

Water-soluble composition, preparation method and application thereof
Technical Field
The invention relates to the field of magnolia officinalis total phenol derivatives, in particular to a composition of magnolia officinalis total phenol derivatives and a preparation method and application thereof.
Background
The food, the medicine and the cosmetics are rich in a large amount of water and various nutritional ingredients, a good growth environment is provided for microorganisms, and the microorganisms are difficult to invade in the production and use processes of the cosmetics, so that the cosmetics are extremely easy to decay, the quality of the products is reduced, and the health of users is threatened. The addition of the preservative into the cosmetics is an important means for protecting the products from microbial contamination, prolonging the shelf life of the products and ensuring the safety of the products.
Currently, many kinds of preservatives are used in foods, medicines and cosmetics, most of them are chemical preservatives, and dozens of them are commonly used, including acidic preservatives (benzoic acid), ester-type preservatives (parabens) and the like. However, with the development of science and the increasing awareness of safety of consumers, it is gradually found that although chemical preservatives have a good antiseptic effect, some chemical preservatives can produce adverse effects on human bodies, cause skin allergy, decrease physical functions and pollute the environment. Therefore, natural preservatives are urgently needed by various industries, and a natural preservative with low toxicity, low irritation and high performance has great significance in the fields of food, medicines, cosmetics and the like.
Cortex magnoliae officinalis (Magnolia officinalis cortex) is dried bark, root bark and branch of Magnolia officinalis linasl srehd.et wils, belonging to important traditional Chinese medicinal materials and being listed as a high-quality product in the Shennong Ben Cao Jing. Cortex Magnolia officinalis is bitter and pungent, warm in nature, and has effects in promoting qi circulation, eliminating dampness, warming middle warmer, relieving pain, lowering adverse qi, and relieving asthma. The main chemical active ingredients of the magnolia officinalis are lignans, magnolol, honokiol and the like. The phenols in cortex Magnolia officinalis have antibacterial, antitumor, analgesic, and antiinflammatory effects. But because the water solubility is poor, the mangnolia officinalis total phenols are easy to oxidize and deteriorate, and the application of the mangnolia officinalis total phenols in foods, medicines and cosmetics is greatly hindered. Generally, the general surfactants and emulsifiers can be used for solubilizing the total magnolol, in this case, the dosage of the required surfactants and emulsifiers is very large, and even if the total magnolol is applied to an aqueous formula, the total magnolol can be separated out from the aqueous formula, so that the whole system becomes white and turbid, and the use is seriously influenced. In addition, a small amount of alkali can be added into the formula system to convert the total phenols of the magnolia officinalis into salts and increase the water solubility of the total phenols of the magnolia officinalis, and the total phenols of the magnolia officinalis formed by the method are extremely unstable and easily become golden yellow, so that the conductivity of the system is increased and the bacteriostatic ability is reduced. The above method has very high requirements on the pH of a product formula system and the dosage accuracy of a thickener and an emulsifier, so that the method is basically difficult to process and apply.
The traditional method for improving the solubility of the total phenols of magnolia officinalis introduces impurity compounds into a protogen system, and the thick total phenols of magnolia officinalis are unstable after being dissolved in an aqueous solution system, so that the system is easy to deteriorate, and the bacteriostatic ability is reduced. Therefore, the modification of the structure of the total phenols of the magnolia officinalis improves the solubility and the bacteriostatic ability of the total phenols of the magnolia officinalis in water, and is a problem to be solved urgently when the total phenols of the magnolia officinalis are used as natural preservatives to be applied to foods, medicines and cosmetics.
Disclosure of Invention
The invention aims to solve the problems of poor water solubility of the total phenols of magnolia officinalis and reduced bacteriostatic ability after the total phenols of magnolia officinalis are dissolved in an aqueous solution system, and provides a composition of the total phenols of magnolia officinalis and a preparation method and application thereof. The water-soluble magnolia total phenol derivative provided by the invention has excellent stability and bacteriostatic ability when being applied to a preservative.
In order to achieve the above object, in a first aspect, the present invention provides a water-soluble composition consisting of a compound having a structure of formula (1) and a compound having a structure of formula (2):
Figure BDA0002209728320000021
wherein the content of the compound with the structure of the formula (1) in the water-soluble composition is 20-80 wt%.
According to the invention, in the formulae (1) and (2), R1、R2、R3And R4Each independently selected from hydrogen, halogen, substituted or unsubstituted C1-C10Alkyl, substituted or unsubstituted C1-C12Alkoxy, substituted or unsubstituted C6-C10Aryl group of (1).
Preferably, R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from halogen, C1-C6Alkoxy and C6-C10Aryl group of (1).
Preferably, R1、R2、R3And R4Each independently is substituted or unsubstituted C1-C10Alkyl group of (1).
Preferably, R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C6Alkoxy of the general formula-O-R9-a radical of the OH structure.
Wherein R is9Is C1-C6An alkylene group of (a).
Preferably, R5、R6、R7And R8Each independently selected from hydrogen and C6-C10Aryl and C1-C6Alkyl group of (1).
In a second aspect, the present invention provides a method for preparing a water-soluble composition, which comprises first contacting a compound having a structure of formula (3) and/or (4) with a compound having a structure of formula (5) and/or (6) under Mannich reaction conditions, and then second contacting the product of the first contacting with a composition consisting of a compound having a structure of formula (7) and a compound having a structure of formula (8) to obtain a Mannich reaction product.
Wherein the content of the compound with the structure of the formula (1) in the water-soluble composition is 20-80 wt%.
Preferably, in formula (3) and formula (5), R1、R2、R3And R4Each independently is substituted or unsubstituted C1-C10Alkyl group of (1).
Preferably, R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C6Alkoxy of the general formula-O-R9-a radical of the OH structure.
Wherein R is9Is C1-C6An alkylene group of (a).
Preferably, in formula (4) and formula (6), R5、R6、R7And R8Each independently selected from hydrogen and C6-C10Aryl and C1-C6Alkyl group of (1).
Preferably, in formula (7) and formula (8), R1、R2、R3And R4Each independently selected from hydrogen, halogen, substituted or unsubstituted C1-C10Alkyl, substituted or unsubstituted C1-C12Alkoxy, substituted or unsubstituted C6-C10Aryl group of (1).
Preferably, R1、R2、R3And R4Optionally toThe substituents present are each independently selected from halogen, C1-C6Alkoxy and C6-C10Aryl group of (1).
In a third aspect, the invention provides the use of the water-soluble composition in bacteriostasis.
The modified magnolia officinalis total phenol derivative which can be used for bacteriostasis is prepared by modifying the structure of the magnolia officinalis total phenol, has good water solubility, is colorless and transparent after being dissolved, has obvious inhibition effect on common gram-negative bacteria, gram-positive bacteria, fungi and the like, and can be used as a green and natural preservative to be applied to the fields of food, medicines, cosmetics and the like.
Additional features and advantages of the invention will be set forth in the detailed description which follows.
Detailed Description
The following is a detailed description of specific embodiments of the present invention. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
Some of the terms referred to in this aspect are explained below:
“C1-C10the "alkyl group" of (a) represents an alkyl group having 1 to 10 carbon atoms in total, and includes a straight-chain alkyl group, a branched-chain alkyl group or a cyclic alkyl group, and specifically may be a straight-chain alkyl group, a branched-chain alkyl group or a cyclic alkyl group having 1, 2,3, 4, 5, 6, 7, 8, 9, 10 carbon atoms in total, and may be, for example, a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a n-butyl group, an isobutyl group, a tert-butyl group, a n-pentyl group, an isopentyl group, a n-hexyl group, a,Methylcyclopropyl, ethylcyclopropyl, cyclopentyl, methylcyclopentyl, cyclohexyl, and the like.
“C1-C12The "alkoxy group" of (b) represents an alkoxy group having 1 to 12 carbon atoms in total, and includes a linear alkoxy group, a branched alkoxy group and a cycloalkoxy group, and specifically may be a linear alkoxy group, a branched alkoxy group or a cycloalkoxy group having 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12 carbon atoms in total, and may be, for example, a methoxy group, an ethoxy group, a n-propoxy group, an isopropoxy group, a n-butoxy group, an isobutoxy group, a t-butoxy group, a n-pentoxy group, an isopentoxy group, a n-hexoxy group, a n-heptoxy group, a n-octoxy group, a n-nonoxy group, a n-decoxy group, a cyclopropoxy group, a methyl cyclopropoxy.
“C6-C10The "aryl group" of (a) represents an aryl group having 6 to 10 carbon atoms in total, at least one H group being substituted by C on the benzene ring of the aryl group1-C4And alkyl group of (a) is substituted, for example, tolyl, ethylphenyl, n-propylphenyl, isopropylphenyl, n-butylphenyl, orthoxylyl, m-xylyl, p-xylyl, etc.
Other similar groups are defined herein with reference to the foregoing definitions, only with respect to the number of carbon atoms or the manner of isomerisation.
In a first aspect, the present invention provides a water-soluble composition consisting of a compound having the structure of formula (1) and a compound having the structure of formula (2):
Figure BDA0002209728320000061
wherein the content of the compound with the structure of the formula (1) in the water-soluble composition is 20-80 wt%.
Preferably, in formula (1) and formula (2), R1、R2、R3And R4Each independently selected from hydrogen, halogen, substituted or unsubstituted C1-C10Alkyl, substituted or unsubstituted C1-C12Alkoxy, substituted or unsubstituted C6-C10Aryl group of (1).
Preferably, R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from halogen, C1-C6Alkoxy and C6-C10Aryl group of (1).
Preferably, R1、R2、R3And R4Each independently is substituted or unsubstituted C1-C10Alkyl group of (1).
Preferably, R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C6Alkoxy of the general formula-O-R9-a radical of the OH structure.
Wherein R is9Is C1-C6An alkylene group of (a).
Preferably, R5、R6、R7And R8Each independently selected from hydrogen and C6-C10Aryl and C1-C6Alkyl group of (1).
According to a preferred embodiment of the present invention, wherein, in the formulae (1) and (2), R1、R2、R3And R4Each independently selected from hydrogen, fluorine, chlorine, bromine, substituted or unsubstituted C1-C5Alkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C6-C8Aryl group of (1).
Preferably, R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from fluorine, chlorine, bromine, C1-C3Alkoxy and C6-C8Aryl group of (1).
R1、R2、R3And R4Each independently is substituted or unsubstituted C1-C5Alkyl group of (1).
R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C3Alkoxy group of,The general formula is-O-R9-a radical of the OH structure.
Wherein R is9Is C1-C3An alkylene group of (a).
Preferably, R1、R2、R3And R4Each independently of the other being methyl,
Figure BDA0002209728320000072
R5、R6、R7And R8Each independently selected from hydrogen and C6-C8Aryl and C1-C3Alkyl groups of (a);
preferably, in formula (1) and formula (2), R5、R6、R7And R8Are all hydrogen.
According to a preferred embodiment of the present invention, in the water-soluble composition, the compound having the structure of formula (1) is selected from at least one of the following compounds:
compound 1:
compound 2:
compound 3:
compound 4:
compound 5:
Figure BDA0002209728320000092
wherein the compound with the structure of the formula (2) is selected from at least one of the following compounds:
compound 6:
Figure BDA0002209728320000093
compound 7:
Figure BDA0002209728320000101
compound 8:
Figure BDA0002209728320000102
compound 9:
compound 10:
Figure BDA0002209728320000111
the inventor of the invention finds that the composition of the magnolia total phenol derivative in the preferred embodiment has more excellent water solubility and bacteriostatic ability.
In a second aspect, the present invention provides a method for preparing a water-soluble composition, which comprises first contacting a compound having a structure of formula (3) and/or (4) with a compound having a structure of formula (5) and/or (6) under Mannich reaction conditions, and then second contacting the product of the first contacting with a composition consisting of a compound having a structure of formula (7) and a compound having a structure of formula (8) to obtain a Mannich reaction product.
Figure BDA0002209728320000112
Wherein the content of the compound with the structure of the formula (1) in the water-soluble composition is 20-80 wt%.
Preferably, in formula (3) and formula (5), R1、R2、R3And R4Each independently is substituted or unsubstituted C1-C10Alkyl group of (1).
R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C6Alkoxy of the general formula-O-R9-a radical of the OH structure.
Wherein R is9Is C1-C6An alkylene group of (a).
Preferably, in formula (4) and formula (6), R5、R6、R7And R8Each independently selected from hydrogen and C6-C10Aryl and C1-C6Alkyl group of (1).
Preferably, in formula (7) and formula (8), R1、R2、R3And R4Each independently selected from hydrogen, halogen, substituted or unsubstituted C1-C10Alkyl, substituted or unsubstituted C1-C12Alkoxy, substituted or unsubstituted C6-C10Aryl group of (1).
R1、R2、R3And R4Each of the substituents optionally present on (A) is independently selected from halogen, C1-C6Alkoxy and C6-C10Aryl group of (1).
According to the present invention, the compound having the structure of formula (3) and/or formula (5) is an amine compound, and the amine is not particularly limited in the present invention, and may be a linear alkylamine, a branched alkylamine, a cycloalkylamine, a hydroxyalkylamine, or various amino acids, and preferably a secondary amine thereof, and the secondary amine is not particularly limited in the present invention, and preferably is at least one of N-methyl-glycine, N-ethyl-glycine, N-methyl-aminoethoxyethanol, N-ethyl-aminoethoxyethanol, methylaminoacetaldehyde dimethyl acetal, methylaminoacetaldehyde diethyl acetal, ethylaminoacetaldehyde dimethyl acetal, diethanolamine, dimethylamine, diethylamine, and di-N-propylamine.
Preferably, the molar ratio of the total amount of the compound having the structure of formula (2) and/or formula (4), the total amount of the compound having the structure of formula (4) and/or formula (6), and the composition consisting of the compounds having the structures of formula (7) and formula (8) is 0.5 to 6: 0.5-6: 1, preferably 1 to 4: 1-4: 1.
preferably, the compound having the structure of formula (4) and/or formula (6) is an aldehyde compound, and the aldehyde compound is not particularly limited in the present invention, and for example, the aldehyde selected may be at least one of formaldehyde, acetaldehyde, propionaldehyde, and benzaldehyde, and is preferably formaldehyde.
According to a preferred embodiment of the present invention, the first and second contacting are carried out in the presence of an acidic substance and a solvent, wherein the solvent is water and/or an organic solvent. The acidic substance is not particularly limited, and may be at least one of hydrochloric acid, sulfuric acid, phosphoric acid, or acetic acid.
According to a preferred embodiment of the present invention, the first and second contacting are carried out in the presence of water and/or an organic solvent, which is not particularly limited in the present invention and may be conventionally selected in the art, preferably a polar organic solvent, further preferably a polar solvent containing a hydroxyl group or a carbonyl group, for example, the organic solvent is preferably selected from methanol, ethanol and acetic acid, preferably methanol and/or ethanol.
According to a preferred embodiment of the present invention, the method for preparing the composition of the magnolia total phenol derivative comprises the steps of mixing the compound having the structure of formula (3) and/or formula (5) with the compound having the structure of formula (4) and/or formula (6) under Mannich reaction conditions for first contact, and then carrying out second contact on the product obtained by the first contact and the composition of the compound having the structure of formula (7) and the compound having the structure of formula (8). In the first contact, the aldehyde compound is first contacted with the secondary amine compound at a temperature of 20 to 50 deg.C, preferably 30 to 40 deg.C, for 5 to 20min, preferably 10 to 15 min. The aldehyde compound may be in the form of a solution, and the solvent of the solution is water. Subsequently, the first contacted system is placed in a low-temperature water bath, the acidic substance or the solution of the acidic substance in the organic solvent is added into the system, the temperature is controlled to be 1-10 ℃, preferably 2-5 ℃, and the continuous contact time is 0.5-2h, preferably 0.6-1.5 h. In the present invention, the timing of adding the acidic substance is not particularly limited, and the acid may be added at the same time as the first contact, and preferably, the acid is added to the organic solvent first and then added together with the organic solvent. The inventors of the present invention have found that the above preferred mode is effective in reducing acid mist and avoiding the side reaction due to the exothermic heat of reaction, as compared with the mode in which the acid is directly added to the reactants. The low-temperature water bath is not particularly limited, and may be selected conventionally in the field, and is preferably an ice salt bath, and the salt in the ice salt bath is not particularly limited, and is preferably at least one of potassium chloride, sodium sulfate, and potassium sulfate. In the ice salt bath, the amount of the salt is 0.5 to 5 wt% based on the weight of water.
Preferably, the second contacting is carried out at a temperature of from 30 to 90 deg.C, preferably from 70 to 85 deg.C, for a period of from 1 to 3 hours, preferably from 1.5 to 2 hours.
According to the present invention, preferably, the method further comprises: the product of the second contact of step (ii) is evaporated and purified in sequence. The evaporation operation is not particularly limited in the invention and can be selected conventionally in the field, and the invention adopts a rotary evaporator to evaporate and remove most of the organic solvent; the purification operation is not particularly limited in the present invention, and may be a conventional operation in the field, preferably purification is performed by column chromatography, the purification packing is 100-200 mesh silica gel, the eluent is not particularly limited and may be a conventional choice in the field, preferably, the eluent is ethyl acetate/acetone, and the volume ratio of ethyl acetate and acetone is preferably 2-6:1, and particularly preferably 4: 1.
According to the invention, preferably, the compound with the structure of the formula (7) and the compound with the structure of the formula (8) are both from plant extracts, the plant in the invention is magnolia officinalis belonging to magnoliaceae, and the content of the composition of the compound with the structure of the formula (7) and the compound with the structure of the formula (8) in the extracts is more than or equal to 80%.
In a third aspect, the invention also provides an application of the water-soluble composition in bacteriostasis.
The magnolia total phenol derivative provided by the invention can be applied to food, medicine and cosmetics, can be used as a preservative or a preservative component, and has an inhibiting effect on common escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, candida albicans, aspergillus niger and the like. The total phenol derivative of Magnolia officinalis is used in an amount of 0.001-0.01 g per gram of the food, medicine or cosmetic.
The present invention will be described in detail below by way of examples. In the following examples, the molecular structure of the prepared magnolia total phenol derivative is measured by a flight time mass spectrometer, a nuclear magnetic resonance spectrometer and a liquid chromatography mass spectrometer, wherein the flight mass spectrometer is of the type HR EI-TOFMS and is purchased from Kore company in UK; the model of the nmr spectrometer was semer femospin 80, purchased from semer femtole corporation; the model of the liquid chromatography-mass spectrometer is a TSQ Altis triple quadrupole mass spectrometer purchased from Saimer Fei company; the content of the plant-derived magnolia officinalis total phenols is 70%, 80% and 90%, and the magnolia officinalis total phenols are purchased from Hainan Jiamu Biotechnology limited; the N-methyl-glycine powder and N-methyl-aminoglyoxal dimethyl acetal are purchased from Shanghai Merlin biological reagents, Inc.; the nutrient broth is purchased from Beijing Meiruida science and technology Limited and mainly comprises peptone, beef extract, sodium chloride and water; the Sa's medium is purchased from Shandong West Asia chemical industry Co., Ltd, and contains peptone and agar as main ingredients; TTC is short for 2,3, 5-triphenyltetrazolium chloride, and the used TTC reagent is purchased from Shanghai leaf Biotech limited; nipagin methyl ester is analytically pure and purchased from Shanghai Michelin Biochemical technology, Inc.; phenoxyethanol was analytically pure and purchased from Shanghai Aladdin Biotechnology GmbH.
Example 1
1ml of hydrochloric acid with the concentration of 12mol/L is added into 70ml of methanol to prepare methanolic acid solution for later use. Weighing 7.6g of N-methyl-glycine powder, putting the powder into a three-neck flask, slowly dropwise adding 10ml of 37% formaldehyde solution, magnetically stirring, controlling the dropwise adding speed to be 1ml/min and controlling the temperature to be 30-35 ℃. Under the condition of ice-water bath, 40ml of prepared methanolic acid solution is added into a three-neck flask, the dropping speed is controlled to be 4ml/min, the temperature is controlled to be 2-5 ℃, and magnetic stirring is continued for 1 hour. 13.3g of plant-derived Magnolia officinalis total phenols (70% content) was weighed out and dissolved in the remaining 30ml of methanolic acid solution. Putting the three-neck flask in an oil bath, controlling the temperature to be 85 ℃, adding a methanolic acid solution of the total phenols of the mangnolia officinalis, condensing and refluxing, and reacting for 12 hours. Removing excessive methanol by using a rotary evaporator, purifying by using a 200-mesh silica gel column, eluting with ethyl acetate/acetone at a volume ratio of 4:1, combining the eluates, concentrating, and freeze-drying to obtain the Magnolia officinalis total phenol derivative. The yield is 35 percent based on the total phenols of the magnolia officinalis in the reaction raw materials. The general magnolol derivative is characterized by using flight mass spectrum and nuclear magnetic resonance, and is proved to be the general magnolol derivative with the structure shown in the formula (1) and the formula (2). The mechanism of the reaction is as follows:
Figure BDA0002209728320000151
Figure BDA0002209728320000161
example 2
1ml of hydrochloric acid with the concentration of 12mol/L is added into 70ml of methanol to prepare methanolic acid solution for later use. Weighing 11.3g of 40% dimethylamine solution, putting the dimethylamine solution into a three-neck flask, slowly dripping 10ml of 37% formaldehyde solution, magnetically stirring, controlling the dripping speed to be 1ml/min and controlling the temperature to be 30-35 ℃. Under the condition of ice-water bath, 40ml of prepared methanolic acid solution is added into a three-neck flask, the dropping speed is controlled to be 4ml/min, the temperature is controlled to be 2-5 ℃, and magnetic stirring is continued for 1 hour. 13.3g of plant-derived Magnolia officinalis total phenols (80% content) was weighed out and dissolved in the remaining 30ml of methanolic acid solution. Putting the three-neck flask in an oil bath, controlling the temperature to be 75 ℃, adding a methanol solution of the total magnolol, condensing and refluxing, and reacting for 6 hours. Removing excessive methanol by using a rotary evaporator, purifying by using a 200-mesh silica gel column, eluting with ethyl acetate/acetone at a volume ratio of 4:1, combining the eluates, concentrating, and freeze-drying to obtain the Magnolia officinalis total phenol derivative. The yield is 74 percent based on the total phenols of the magnolia officinalis in the reaction raw materials. The general magnolol derivative is characterized by using flight mass spectrum and nuclear magnetic resonance, and is proved to be the general magnolol derivative with the structure shown in the formula (1) and the formula (2). The mechanism of the reaction is as follows:
Figure BDA0002209728320000171
example 3
1ml of hydrochloric acid with the concentration of 12mol/L is added into 70ml of methanol to prepare methanolic acid solution for later use. Weighing 13g of diethanolamine, putting the diethanolamine into a three-neck flask, slowly dropwise adding 10ml of 37% formaldehyde solution, magnetically stirring, controlling the dropwise adding speed to be 1ml/min, and controlling the temperature to be 30-35 ℃. In an ice-water bath, 40ml of prepared methanolic acid solution is added into a three-neck flask, the dropping speed is controlled to be 4ml/min, the temperature is controlled to be 2-5 ℃, and magnetic stirring is continued for 1 h. Weighing 10g of plant-derived total phenols (content: 90%), and dissolving in the rest 30ml of methanol acid solution. Putting the three-neck flask in an oil bath, controlling the temperature to be 70 ℃, adding a methanol solution of the total magnolol, condensing and refluxing, and reacting for 6.5 hours. Removing excessive methanol by using a rotary evaporator, purifying by using a 200-mesh silica gel column, eluting with ethyl acetate/acetone at a volume ratio of 4:1, combining the eluates, concentrating, and freeze-drying to obtain the Magnolia officinalis total phenol derivative. The yield is 92 percent based on the total phenols of the magnolia officinalis in the reaction raw materials. The general magnolol derivative is characterized by using flight mass spectrum and nuclear magnetic resonance, and is proved to be the general magnolol derivative with the structure shown in the formula (1) and the formula (2). The mechanism of the reaction is as follows:
Figure BDA0002209728320000172
Figure BDA0002209728320000181
test example 1
The solubility test method is as follows: a measuring cylinder is used to measure 25 +/-1 ℃ and 100g of deionized water, and the deionized water is put into a 250ml beaker. Put into a magnetic stirrer, and the rotating speed is adjusted to be 200 rmp/min. The samples from examples 1, 2 and 3 were weighed on an analytical balance and dissolved in deionized water in an amount of 0.1g each time until complete dissolution was not achieved after stirring for 10 minutes, and the maximum dissolved mass was recorded. The results are shown in Table 1.
Test example 2
The sample of the magnolia total phenol derivative prepared in the example 3 is used as a test object, and the minimum inhibitory concentration MIC value of the sample is quantitatively tested. A10% Magnolia bark total phenolic ethanol solution, methyl paraben, a traditional chemical preservative, and phenoxyethanol were used as comparative examples.
The test method of the MIC value of the minimum inhibitory concentration comprises the following steps: the sterilized nutrient broth (used for culturing escherichia coli, staphylococcus aureus and pseudomonas aeruginosa) and the saxifrage medium (used for culturing candida albicans and aspergillus niger) are used as diluents, test samples are diluted by a two-fold dilution method, and then the bacteria are inoculated according to the concentrations shown in table 2. Culturing the bacteria at 35 deg.C for 36 h; the fungus was cultured at 28 ℃ for 48 h. And adding a TTC reagent 3h before the end point of the culture, continuing the culture, if the culture solution turns red, determining that the concentration cannot inhibit the growth of the microorganism, and if the culture solution does not turn red, determining that the minimum medicament concentration in the culture solution which does not turn red is the minimum bacteriostatic concentration of the bacteriostatic agent on the microorganism. The specific results are shown in Table 3.
Test example 3
The magnolia total phenol derivative prepared in example 3 was added to the spray formulation as shown in table 4 below. Inoculating certain amount of bacteria and fungi, and detecting microbial quantity change at intervals of 0 day, 7 days, 14 days, 21 days and 28 days according to the detection method of the microbial preservative efficacy test of United states Pharmacopeia USP32<51 >. The results are shown in Table 5 below.
TABLE 1
Quality of dissolution Cortex Magnolia officinalis Total phenols Example 1 Example 2 Example 3
Solvent water (100g) -- >3g >1g >10g
Note: - -means that 0.1g is not completely dissolved; indicates that the sample is totally dissolved
TABLE 2
Figure BDA0002209728320000191
TABLE 3
MIC(%) Example 3 10% Magnolia officinalis total phenol ethanol solution Nipagin methyl ester Phenoxyethanol
Escherichia coli 0.032 1.36 0.156 0.25
Staphylococcus aureus 0.032 0.0049 0.078 0.125
Pseudomonas aeruginosa 0.125 1.32 1.25 1
Candida albicans 0.062 0.0065 0.626 0.25
Aspergillus niger 0.125 0.0063 0.626 0.5
TABLE 4
TABLE 5
As can be seen from the results in Table 1, in the solubility qualitative test, the solubility of the magnolia officinalis total phenol derivative prepared by the invention in 100g of solvent water is more than 1g, namely, the sample prepared in the example is completely dissolved, while the magnolia officinalis total phenol extracted from the plant is not soluble in water; the data in table 3 show that the magnolia total phenol derivative prepared in example 3 has significant bacteriostatic action on escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, candida albicans and aspergillus niger, and the bacteriostatic effect is superior to that of the traditional chemical preservatives, namely methyl paraben and phenoxyethanol; the spray formulation of table 4 provides a very suitable environment for the survival of bacteria and fungi and it can be seen from the data in table 5 that under such harsh conditions the sample prepared in example 3 of the present invention exhibited excellent bacteriostatic ability, as tested by the preservative challenge test for the 28 day water formulation spray, and the magnolia total phenol derivative in example 3 passed the preservative challenge test as a preservative.
Because the total phenol of the magnolia officinalis is not dissolved in water, the bacteriostatic effect is difficult to test. The 10% magnolia total phenol ethanol solution has a good bacteriostatic effect, but the national standard strictly limits the dosage of ethanol in cosmetics, and when the magnolia total phenol ethanol solution is applied to a water system, magnolol and honokiol can be separated out from ethanol, so that the magnolia total phenol ethanol solution cannot be applied industrially.
The magnolia officinalis total phenol derivative obtained by modifying the magnolia officinalis total phenol by adopting the method has good water solubility, and the solubility of the magnolia officinalis total phenol in water is effectively improved; the magnolia total phenol derivative has obvious inhibiting effect on common gram-negative bacteria, gram-positive bacteria, fungi and the like.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.

Claims (10)

1. A water-soluble composition consisting of a compound having the structure of formula (1) and a compound having the structure of formula (2):
Figure FDA0002209728310000011
wherein the content of the compound with the structure of the formula (1) in the water-soluble composition is 20-80 wt%;
in the formulae (1) and (2), R1、R2、R3And R4Each independently selected from hydrogen, halogen, substituted or unsubstituted C1-C10Alkyl, substituted or unsubstituted C1-C12Alkoxy, substituted or unsubstituted C6-C10Aryl of (a);
R1、R2、R3and R4Each of the substituents optionally present on (A) is independently selected from halogen, C1-C6Alkoxy and C6-C10Aryl of (a);
R1、R2、R3and R4Each independently is substituted or unsubstituted C1-C10Alkyl groups of (a);
R1、R2、R3and R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C6Alkoxy of the general formula-O-R9-a group of OH structure;
wherein R is9Is C1-C6An alkylene group of (a);
R5、R6、R7and R8Each independently selected from hydrogen and C6-C10Aryl and C1-C6Alkyl group of (1).
2. The water-soluble composition of claim 1, which isIn the formulae (1) and (2), R1、R2、R3And R4Each independently selected from hydrogen, fluorine, chlorine, bromine, substituted or unsubstituted C1-C5Alkyl, substituted or unsubstituted C1-C6Alkoxy, substituted or unsubstituted C6-C8Aryl of (a);
R1、R2、R3and R4Each of the substituents optionally present on (A) is independently selected from fluorine, chlorine, bromine, C1-C3Alkoxy and C6-C8Aryl of (a);
R1、R2、R3and R4Each independently is substituted or unsubstituted C1-C5Alkyl groups of (a);
R1、R2、R3and R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C3Alkoxy of the general formula-O-R9-a group of OH structure;
wherein R is9Is C1-C3An alkylene group of (a);
R5、R6、R7and R8Each independently selected from hydrogen and C6-C8Aryl and C1-C3Alkyl groups of (a);
preferably, in formula (1) and formula (2), R5、R6、R7And R8Are all hydrogen.
3. The water-soluble composition according to claim 1 or 2, wherein the compound having the structure of formula (1) is selected from at least one of the following compounds:
compound 1:
Figure FDA0002209728310000021
compound 2:
Figure FDA0002209728310000031
compound 3:
compound 4:
Figure FDA0002209728310000033
compound 5:
Figure FDA0002209728310000041
wherein the compound with the structure of the formula (2) is selected from at least one of the following compounds:
compound 6:
Figure FDA0002209728310000042
compound 7:
Figure FDA0002209728310000043
compound 8:
compound 9:
Figure FDA0002209728310000052
compound 10:
4. a method for preparing a water-soluble composition, which is characterized by comprising the steps of carrying out first contact on a compound with a structure shown in a formula (3) and/or a formula (4) and a compound with a structure shown in a formula (5) and/or a formula (6) under Mannich reaction conditions, and then carrying out second contact on a product obtained by the first contact and a composition consisting of the compound with a structure shown in a formula (7) and the compound with a structure shown in a formula (8) to obtain a Mannich reaction product;
wherein the content of the compound represented by the formula (7) and the content of the compound represented by the formula (8) in the composition are not zero;
R1、R2、R3and R4Each independently is substituted or unsubstituted C1-C10Alkyl groups of (a);
R1、R2、R3and R4Each of the substituents optionally present on (A) is independently selected from hydroxy, carboxy, C1-C6Alkoxy of the general formula-O-R9-a group of OH structure;
wherein R is9Is C1-C6An alkylene group of (a);
R5、R6、R7and R8Each independently selected from hydrogen and C6-C10Aryl and C1-C6Alkyl groups of (a);
in the formulae (7) and (8), R1、R2、R3And R4Each independently selected from hydrogen, halogen, substituted or unsubstituted C1-C10Alkyl, substituted or unsubstituted C1-C12Alkoxy, substituted or unsubstituted C6-C10Aryl of (a);
R1、R2、R3and R4Each of the substituents optionally present on (A) is independently selected from halogen, C1-C6Alkoxy and C6-C10Aryl group of (1).
5. The method according to claim 4, wherein the compound having the structure of formula (3) and/or formula (5) is selected from at least one of N-methyl-glycine, N-ethyl-glycine, N-methyl-aminoethoxyethanol, N-ethyl-aminoethoxyethanol, methylaminoacetaldehyde dimethyl acetal, methylaminoacetaldehyde diethyl acetal, ethylaminoacetaldehyde dimethyl acetal, diethanolamine, dimethylamine, diethylamine, di-N-propylamine;
the molar ratio of the total amount of the compound having the structure of formula (3) and/or formula (5), the total amount of the compound having the structure of formula (4) and/or formula (6) to the composition consisting of the compounds having the structures of formula (7) and formula (8) is 0.5 to 6: 0.5-6: 1, preferably 1 to 4: 1-4: 1.
6. the method according to claim 4, wherein the compound having the structure of formula (4) and/or formula (6) is at least one selected from formaldehyde, acetaldehyde, propionaldehyde, benzaldehyde, phenylacetaldehyde, o-methyl benzaldehyde, and preferably formaldehyde.
7. The method of claim 4, wherein the first and second contacting are both performed in the presence of water and/or an organic solvent, and in acidic conditions provided by at least one of hydrochloric acid, phosphoric acid, sulfuric acid, and acetic acid;
preferably, the organic solvent is selected from at least one of methanol, ethanol and acetic acid, preferably methanol and/or ethanol.
8. The method of claim 7, wherein the first contacting comprises adding the compound having the structure of formula (4) and/or formula (6) to the compound having the structure of formula (3) and/or formula (5) at 20-50 ℃, then adding the acidic substance or the solution of the acidic substance in the solvent at 1-10 ℃, and continuing the reaction for 0.5-2 h;
preferably, the second contacting mode comprises dissolving the compounds with the structures of the formula (7) and the formula (8) in the solvent in the presence of an acidic substance to form a solution, and then carrying out the second contacting with the product obtained by the first contacting.
9. Use of a water-soluble composition according to any one of claims 1 to 3 for bacteriostasis.
10. The use according to claim 9, wherein the bacteria are selected from at least one of escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, candida albicans, aspergillus niger; preferably, the bacteria are present in the food, pharmaceutical or cosmetic product in an amount of 0.001-0.01 gram per gram of the food, pharmaceutical or cosmetic product.
CN201910894304.XA 2019-09-20 2019-09-20 Water-soluble composition, preparation method and application thereof Active CN110664795B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910894304.XA CN110664795B (en) 2019-09-20 2019-09-20 Water-soluble composition, preparation method and application thereof
PCT/CN2020/114939 WO2021052269A1 (en) 2019-09-20 2020-09-14 Water-soluble composition, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910894304.XA CN110664795B (en) 2019-09-20 2019-09-20 Water-soluble composition, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN110664795A true CN110664795A (en) 2020-01-10
CN110664795B CN110664795B (en) 2022-12-27

Family

ID=69077295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910894304.XA Active CN110664795B (en) 2019-09-20 2019-09-20 Water-soluble composition, preparation method and application thereof

Country Status (2)

Country Link
CN (1) CN110664795B (en)
WO (1) WO2021052269A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021052271A1 (en) * 2019-09-20 2021-03-25 广东省禾基生物科技有限公司 Magnolol derivative and preparation method therefor and application thereof
WO2021052269A1 (en) * 2019-09-20 2021-03-25 广东省禾基生物科技有限公司 Water-soluble composition, preparation method and application thereof
WO2021052270A1 (en) * 2019-09-20 2021-03-25 广东省禾基生物科技有限公司 Honokiol derivative, preparation method therefor and use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2459338A (en) * 1944-04-22 1949-01-18 Parke Davis & Co Amino methyl phenols
CN1441664A (en) * 2000-05-10 2003-09-10 高露洁-棕榄公司 Synergistic antiplaque/antigivitis oral composition
KR20060014203A (en) * 2004-08-10 2006-02-15 바이오스펙트럼 주식회사 Magnolol and honokiol as a effective compound for acne, one of skin diseases
CN101125801A (en) * 2007-08-22 2008-02-20 肖文军 Highly effective extraction method for magnolol and honokiol crude extract
FR2918560A1 (en) * 2007-07-12 2009-01-16 Oreal Composition, useful for manufacturing products for cosmetic care of skin, lips, nails, hair, eyelashes, eyebrows and/or scalp, comprises UV filtering system, dibenzoylmethane derivative type UV-A filter and phenanthrenol compound
CN102046158A (en) * 2008-05-30 2011-05-04 Wm.雷格利Jr.公司 Oral compositions containing enhanced antibacterial combinations of antioxidants and extracts of magnolia
CN105362346A (en) * 2015-01-30 2016-03-02 浙江尖峰健康科技有限公司 Method for preparing high-purity cortex magnoliae officinalis total phenols from cortex magnoliae officinalis peel
CN107098832A (en) * 2016-02-23 2017-08-29 成都译山生物科技有限公司 A kind of honokiol derivative and preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07103056B2 (en) * 1989-02-08 1995-11-08 大塚製薬株式会社 Neuronal degeneration repair or protectant
US10836782B2 (en) * 2015-06-11 2020-11-17 The Medical College Of Wisconsin, Inc. Mito-honokiol compounds and methods of synthesis and use thereof
CN110615742B (en) * 2019-09-20 2021-11-19 广东省禾基生物科技有限公司 Magnolol derivative and preparation method and application thereof
CN110845350B (en) * 2019-09-20 2021-11-19 广东省禾基生物科技有限公司 Honokiol derivative and preparation method and application thereof
CN110664795B (en) * 2019-09-20 2022-12-27 广东省禾基生物科技有限公司 Water-soluble composition, preparation method and application thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2459338A (en) * 1944-04-22 1949-01-18 Parke Davis & Co Amino methyl phenols
CN1441664A (en) * 2000-05-10 2003-09-10 高露洁-棕榄公司 Synergistic antiplaque/antigivitis oral composition
KR20060014203A (en) * 2004-08-10 2006-02-15 바이오스펙트럼 주식회사 Magnolol and honokiol as a effective compound for acne, one of skin diseases
FR2918560A1 (en) * 2007-07-12 2009-01-16 Oreal Composition, useful for manufacturing products for cosmetic care of skin, lips, nails, hair, eyelashes, eyebrows and/or scalp, comprises UV filtering system, dibenzoylmethane derivative type UV-A filter and phenanthrenol compound
CN101125801A (en) * 2007-08-22 2008-02-20 肖文军 Highly effective extraction method for magnolol and honokiol crude extract
CN102046158A (en) * 2008-05-30 2011-05-04 Wm.雷格利Jr.公司 Oral compositions containing enhanced antibacterial combinations of antioxidants and extracts of magnolia
CN105362346A (en) * 2015-01-30 2016-03-02 浙江尖峰健康科技有限公司 Method for preparing high-purity cortex magnoliae officinalis total phenols from cortex magnoliae officinalis peel
CN107098832A (en) * 2016-02-23 2017-08-29 成都译山生物科技有限公司 A kind of honokiol derivative and preparation method and application

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DING LIN等: ""Anti-proliferative activity and structure-activity relationship of honokiol derivatives"", 《 BIOORGANIC & MEDICINAL CHEMISTRY》 *
刘桂兰等: "厚朴总酚对金黄色葡萄球菌的抑菌作用及抗溶血作用", 《畜牧兽医学报》 *
姜宁等: "厚朴皮提取物对马铃薯青枯病菌的抑制作用", 《安徽农业科学》 *
赵纯森,黄俊斌,周茂繁: "厚朴叶中抑菌活性成分鉴别及其防病效果", 《华中农业大学学报》 *
金志强等: "丹皮酚和厚朴酚体外抗菌作用的研究", 《贵州畜牧兽医》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021052271A1 (en) * 2019-09-20 2021-03-25 广东省禾基生物科技有限公司 Magnolol derivative and preparation method therefor and application thereof
WO2021052269A1 (en) * 2019-09-20 2021-03-25 广东省禾基生物科技有限公司 Water-soluble composition, preparation method and application thereof
WO2021052270A1 (en) * 2019-09-20 2021-03-25 广东省禾基生物科技有限公司 Honokiol derivative, preparation method therefor and use thereof
JP2022548784A (en) * 2019-09-20 2022-11-21 グゥアンドン ファジー バイオテック カンパニー リミテッド Magnolol derivative, its production method and use
JP7369864B2 (en) 2019-09-20 2023-10-26 グゥアンドン ファジー バイオテック カンパニー リミテッド Magnolol derivatives, their production methods and uses

Also Published As

Publication number Publication date
WO2021052269A1 (en) 2021-03-25
CN110664795B (en) 2022-12-27

Similar Documents

Publication Publication Date Title
CN110845350B (en) Honokiol derivative and preparation method and application thereof
CN110664795B (en) Water-soluble composition, preparation method and application thereof
CN110615742B (en) Magnolol derivative and preparation method and application thereof
CN110668985B (en) Magnolol derivative and preparation method and application thereof
CN110668981B (en) Magnolol derivative and preparation method and application thereof
CN102643167A (en) Alga endophytic fungus sesquiterpene compound and preparation method and application thereof
CN112851515A (en) Chlorogenic acid derivative for clearing away heat and toxic materials and preparation method thereof
Fan et al. Methylene-bridged dimeric natural products involving one-carbon unit in biosynthesis
Lu et al. A new method for ellagic acid production from pomegranate husk
CN102659912A (en) Oxygen-rich disesquiterpenes compound, and preparation method and application thereof
CN112851512A (en) Chlorogenic acid derivative for clearing away heat and toxic materials and preparation method thereof
CN113336628A (en) Diol rosalkane, preparation method and application thereof
Ahmad et al. High performance liquid chromatography (HPLC) profiling analysis and bioactivity of baeckea frutescens L.(Myrtaceae)
CN112970787A (en) Anise fennel plant antiseptic and bacteriostatic composition and preparation process and application thereof
Mohamed et al. Synthesis and antimicrobial activity of nitrobenzyl-oxy-phenol derivatives
CN113499337B (en) Application of kurarinone in preparation of aquatic pathogenic bacteria resistant medicines or feed additives
CN104447330B (en) A kind of method preparing antiseptic-germicide from pine needle
CN102659547B (en) Ophiobolin sesterterpene compound and preparation and application thereof
KR102053662B1 (en) Novel Aspergillus niger A-T1 strain and a production of natural antibiotics by using it
CN111018822B (en) Compound with bacteriostatic action, preparation method thereof and application thereof in cigarettes
KR20120090357A (en) Method for extraction of anti bacterial in ginger
CN103788157A (en) Novel coumarin derivative in Fraxinus velutina and preparation process and application thereof
KR20120090359A (en) Method for extraction of zingiberene in ginger
Gheda et al. Antibacterial and antioxidant activities of Phlorotannins extracted from Sargassum linifolium brown alga
CN112273385A (en) Application of adducted product of octyl gallate and acrolein in preparation of bacteriostatic agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant